上城：以资本为翼赋能创新，驱动人工智能产业腾飞

Group 1 - The core focus of the news is on the advancements made by Hangzhou Dishi Medical Biotechnology Co., Ltd. in the field of micro-surgical robotic technology, supported by significant investment from Shangcheng Capital Group [1] - Dishi Medical has successfully completed nearly 100 million yuan in Series A financing, with Shangcheng Capital being a key investor, indicating strong confidence in the company's potential to enhance surgical efficiency and safety [1] - Shangcheng Capital Group aims to strengthen its competitive advantage in the healthcare industry through strategic investments in innovative technologies, particularly in the field of ophthalmology [1] Group 2 - Shangcheng Capital Group has actively participated in the development of artificial intelligence as a core emerging industry in Shangcheng District, having invested in over 20 sub-funds, with a total investment scale exceeding 5 billion yuan [2] - The group has designed a tiered service system to provide tailored support for AI companies, including policy alignment, financing support, and market expansion, enhancing the overall business environment [2] - Future plans include establishing a high-quality development industry fund with a total scale of no less than 10 billion yuan over the next three years to further support the growth of strategic emerging industries [2] Group 3 - Shangcheng Capital Group is focused on accelerating the integration of resources into the "Golden Left Bank" AI industrial belt and fostering an innovative ecosystem for embodied intelligence [3] - The group aims to promote deep integration of industrial and innovation chains, creating a collaborative ecosystem that enhances the synergy between upstream and downstream industries [3]